Medivis

Executive Summary

Medivis is a New York-based surgical intelligence company that leverages augmented reality (AR) and artificial intelligence (AI) to transform surgical navigation and planning. Founded in 2016, the company has developed SurgicalAR, an FDA-cleared platform that converts 2D medical images (e.g., CT, MRI) into interactive 3D holograms for use in cranial, spine, and prostate procedures. This technology enhances surgical precision, reduces operative time, and improves outcomes by providing surgeons with intuitive, hands-free access to patient anatomy during operations. Medivis addresses a significant market need for minimally invasive surgery, where accurate navigation is critical. The platform's ability to overlay real-time holograms onto the surgical field differentiates it from traditional navigation systems, which rely on separate screens and lack depth perception. With no disclosed funding rounds or valuation, Medivis appears to be an early-stage company with strong intellectual property and regulatory traction. The growing adoption of AR/VR in healthcare, particularly in surgery, presents a substantial opportunity. However, the company faces competition from established players like Stryker (Navio) and Brainlab, as well as other AR start-ups such as Proprio. Medivis's success will depend on expanding its regulatory approvals, forging strategic partnerships, and scaling commercial adoption. Overall, the company represents a promising but early-stage investment, with a conviction score of 65 out of 100.

Upcoming Catalysts (preview)

• Q4 2026FDA clearance for additional surgical indications (e.g., orthopedic oncology, minimally invasive spine)75% success
• Q2 2027Strategic partnership with a major hospital system or medical device manufacturer (e.g., Johnson & Johnson, Medtronic)40% success
• Q3 2026Series C funding round or revenue milestone announcing commercial traction50% success